Nasonex (Mometasone Furoate)

Mometasone furoate, the active ingredient in Nasonex, is a corticosteroid presented as a nasal spray for nasal use. It reduces nasal inflammation associated with allergic rhinitis and nasal polyps, providing symptom relief such as congestion, sneezing and runny nose in adults and children as prescribed.

GNH USA supplies Nasonex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, and clinics worldwide, with capabilities for bulk and unit‑dose shipments, regulatory support, and quality‑assured product handling through established distribution networks globally.

Nasonex (mometasone furoate) is a nasal corticosteroid used to manage inflammatory conditions of the nasal passages.

Allergic rhinitis: reduces nasal congestion, sneezing, itching and rhinorrhea. Nasal polyps: decreases polyp size and improves nasal airflow. Seasonal allergic rhinitis: controls symptoms during pollen exposure periods.

Nasonex may cause local and systemic adverse reactions.

Common Side Effects: - Nasal irritation or burning sensation. - Headache. - Epistaxis (nosebleeds). - Throat irritation or dryness. - Cough. - Altered taste perception.

Serious or Rare Side Effects: - Nasal septal perforation. - Severe allergic reaction (anaphylaxis). - Visual disturbances or cataract formation. - Adrenal suppression with prolonged high‑dose use. - Opportunistic fungal infection of the nasal passages. - Elevated intra‑ocular pressure.

Before using Nasonex, consider the following safety measures.

Pregnancy: consult a healthcare provider before initiating therapy. Pediatric use: safety established for children aged ≥2 years; follow prescriber guidance. Concurrent infection: avoid if an active nasal infection is present. Surgery: inform the surgeon as the spray may increase bleeding risk. Long‑term use: monitor for signs of adrenal suppression. Store at room temperature: keep in the original container, protect from moisture and heat.

Nasonex can interact with other medications; review the following categories.

Major Interactions (Avoid): - Systemic corticosteroids: may increase overall glucocorticoid exposure. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise local mometasone levels.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., azole antifungals, ritonavir): monitor for enhanced effects. - Immunosuppressants: watch for additive immunosuppression. - Live vaccines: effectiveness may be reduced; consider timing of administration.